Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05274100 · ClinicalTrials.gov registry record · Phase 1
Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 394
- Enrollment target
NCT05274100: Completed Phase 1 study, sponsored by AbbVie.
NCT05274100 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 394 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (557% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05274100, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 394 participants
- Enrollment target
Study Summary
The primary objectives of this study are to assess the relative bioavailability of risankizumab in on-body delivery system (OBDS) versus the prefilled syringe (PFS) (Substudy 1) and to assess the relative bioavailability of risankizumab in the to-be-marketed Dose A liquid vial versus the Dose B liquid vial used in the Phase 3 studies (Substudy 2).
Primary Outcome
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Interventions
- DRUG Risankizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2021-07-06 |
| Phase | Phase 1 |
What the finished NCT05274100 record still lists
NCT05274100 is an interventional study that assigns participants to a tested intervention. The registered 394 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (557% higher).
The record links to 0 conditions, and to 1 intervention - of which Risankizumab is the first listed.
NCT05274100 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05274100 about?
NCT05274100 is a clinical study titled "Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants". The primary objectives of this study are to assess the relative bioavailability of risankizumab in on-body delivery system (OBDS) versus the prefilled syringe (PFS) (Substudy 1) and to assess the relative bioavailability of risankizumab in the to-be-marketed Dose A liquid vial versus the Dose B liqu...
What is the current status of trial NCT05274100?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 394 participants. The study started on 2020-09-01. Estimated completion is 2021-07-06.
What interventions are being tested in trial NCT05274100?
The interventions under investigation include: Risankizumab (DRUG).
Who is sponsoring clinical trial NCT05274100?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05274100's enrollment target sits among peer trials
394 77th of 2000 higher than 1,924 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06657924 · 394 participants · Phase 2
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
- NCT07225660 · 394 participants · NA
Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)
- NCT07207369 · 395 participants · Phase 3
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
- NCT05640999 · 393 participants · Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI